Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

143.26 +1.47 (+1.04%)
Official Closing Price Updated: 7:00 PM EDT, Jun 12, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,242,788
Open 143.52
Bid (Size) 143.04 (1)
Ask (Size) 144.57 (1)
Prev. Close 141.79
Today's Range 142.00 - 144.50
52wk Range 75.56 - 144.50
Shares Outstanding N/A
Dividend Yield 1.23%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Ozempic Maker Novo Nordisk Closes In On Lego As Denmark's Most Valuable Brand: Report
Novo Nordisk is challenging Lego A/S for the title of Denmark's most valuable brand, with its brand value surging 59% to $5.1 billion. This growth is fueled by the global popularity of its weight-loss... 
Via Benzinga
Humans Clamor For Weight Loss Drugs, But The Next Users Could Be... Pets?
Could GLP-1 drugs for weight loss in pets be the next big thing? Success of Novo Nordisk and Eli Lilly in human market could pave the way. 
Via Benzinga

Performance

YTD
+40.30%
+40.30%
1 Month
+8.19%
+8.19%
3 Month
+7.32%
+7.32%
6 Month
+44.85%
+44.85%
1 Year
+81.77%
+81.77%

More News

Read More
7 Trending Stocks With Momentum on Their Side
Via InvestorPlace
Is Eli Lilly the Best Pharmaceutical Stock for You?
Via The Motley Fool
Jim Cramer Sees Eli Lilly As More Than A 'One-Trick Pony' After FDA Advisors Back Its Alzheimer's Drug: 'It's Ultimately Headed To A Trillion Dollar Valuation'
Via Benzinga
Exposures Product Safety
6 Analysts Have This To Say About Novo Nordisk
Via Benzinga
Novo Nordisk's Options Frenzy: What You Need to Know
Via Benzinga
Structure Therapeutics Stock Could Rocket 87% Higher, According to 1 Wall Street Analyst. Is It Time to Buy?
Via The Motley Fool
Meet The International Megacaps That 'Match Or Surpass' Magnificent Seven Stocks
Via Investor's Business Daily
Abbott Snags U.S. Clearance To Enter The Obesity Arena, Rivaling Dexcom
Via Investor's Business Daily
Exposures Product Safety
The Safety Net Seven: 7 Stocks to Own for Unshakeable Returns
Via InvestorPlace
Week Of June 9: What's In Store For The Markets
Via Talk Markets
Topics Economy
Exposures Economy
Structure Therapeutics' Stock Is Soaring on the Promise of Its Wegovy Competitor, but Is It a Buy?
Via The Motley Fool
Here's Why Demand for Ozempic and Wegovy Could Soar Even Higher
Via The Motley Fool
Profiting from the Crowd: 3 Stocks Set to Surge on Retail Investor Enthusiasm
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Over 10,000 Lawsuits In Novo Nordisk's Ozempic Case Assigned to New Judge
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
ETFs Bet High On Weight Loss Drugs, But Industry Observers Question Long-Term Potential
Via Benzinga
Topics ETFs
Ozempic, Wegovy Create Domino Effect As New Products Emerge Across Industries To Capture New Consumer Habits
Via Benzinga
The 3 Most Undervalued Pharma Stocks to Buy in June 2024
Via InvestorPlace
Topics Economy
Exposures Economy
Why Quality Investors Should Delve into NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) for Investment Opportunities.
Via Chartmill
Is Viking Therapeutics Stock a Buy on the Dip?
Via The Motley Fool
Ozempic Just Got Even More Bullish For Novo Nordisk Stock, Yet Again
Via The Motley Fool
Chinese Generic Ozempic, Wegovy Versions Could Put Novo Nordisk At The Risk Of Stiff Competition In Key Market
Via Benzinga
Biotech Blockbusters: 3 Pharma Stocks to Buy in June for Breakthrough Potential
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.